PTH and osteoporosis: The clinical use of PTH, such as teriparatide, in a dose of 20 μg daily has been shown to decrease the risk of vertebral fractures by 65% and nonvertebral fractures by 53% in patients with osteoporosis after an average of 18 months of therapy.